Cefuroxime Axetil

Recently, Zhejiang Anglikang Pharmaceutical Co., Ltd. has completed the filing and public announcement for a project to produce 4,105 tons of D(-)-Hydroxyphenylglycine Methyl Ester and 1,230 tons of D(-)-Phenylglycine Hydrochloride. The planned investment for this project is 79.91 million yuan, aimed at utilizing the company's existing land resources to build new production facilities, production lines, and supporting ancillary facilities, with a total construction area expected to be 2,900 square meters. The project will employ advanced synthetic process technology and acquire key production equipment such as reactors and condensers. Upon completion, the project is expected to achieve an annual production capacity of 4,015 tons (dry weight) of D(-)-Hydroxyphenylglycine Methyl Ester and 1,230 tons (dry weight) of D(-)-Phenylglycine Hydrochloride, with an anticipated annual output value of 300 million yuan and tax contributions of 20 million yuan. By-products will include 20% hydrochloric acid (5,686.92 tons/year), ammonium sulfate (4,114.2 tons/year), and ammonium chloride (1,191.8 tons/year). D-Hydroxyphenylglycine Methyl Ester is an important raw material used in the enzymatic production of β-lactam antibiotics such as amoxicillin, cefuroxime axetil, cefaclor, and cefepime. According to previous environmental impact assessment reports, Zhejiang Anglikang Pharmaceutical Co., Ltd.'s project to produce 8,000 tons of amoxicillin and 2,000 tons of ampicillin plans to invest 300 million yuan and is expected to have an annual production capacity of 8,000 tons of amoxicillin and 2,000 tons of ampicillin upon completion, with a by-product of ammonium chloride at 3,164.68 tons/year. The current project can be seen as a further extension of the industrial chain. Zhejiang Anglikang Pharmaceutical Co., Ltd. is a modern pharmaceutical enterprise integrating the research, development, production, and sales of pharmaceutical intermediates, active pharmaceutical ingredients, and drug formulations, focusing on cardiovascular, oral cephalosporin, nephrology, and anesthetics. According to the company's latest financial report, in the first three quarters of the year, it achieved operating revenue of 1.122 billion yuan, a year-on-year decrease of 5.51%; the net profit attributable to the parent company was 49.93 million yuan, a year-on-year decrease of 54.52%; and the net profit after deducting non-recurring gains and losses was 39.91 million yuan, a year-on-year decrease of 54.33%.